The Timing of Toxicological Studies to Support Clinical Trials
Editat de C. Parkinson, N. McAuslane, C. Lumley, S.R. Walkeren Limba Engleză Hardback – 31 ian 1995
Toate formatele și edițiile | Preț | Express |
---|---|---|
Paperback (1) | 682.14 lei 43-57 zile | |
SPRINGER NETHERLANDS – 27 sep 2012 | 682.14 lei 43-57 zile | |
Hardback (1) | 688.66 lei 43-57 zile | |
SPRINGER NETHERLANDS – 31 ian 1995 | 688.66 lei 43-57 zile |
Preț: 688.66 lei
Preț vechi: 724.91 lei
-5% Nou
Puncte Express: 1033
Preț estimativ în valută:
131.79€ • 139.38$ • 109.93£
131.79€ • 139.38$ • 109.93£
Carte tipărită la comandă
Livrare economică 30 decembrie 24 - 13 ianuarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9780792388722
ISBN-10: 0792388720
Pagini: 150
Ilustrații: XVI, 150 p.
Dimensiuni: 155 x 235 x 11 mm
Greutate: 0.42 kg
Ediția:1994
Editura: SPRINGER NETHERLANDS
Colecția Springer
Locul publicării:Dordrecht, Netherlands
ISBN-10: 0792388720
Pagini: 150
Ilustrații: XVI, 150 p.
Dimensiuni: 155 x 235 x 11 mm
Greutate: 0.42 kg
Ediția:1994
Editura: SPRINGER NETHERLANDS
Colecția Springer
Locul publicării:Dordrecht, Netherlands
Public țintă
ResearchCuprins
Section I: Introduction and Presentations.- 1 The application of toxicological investigations in the safe development of medicines.- 2 Review of international recommendations on animal toxicity studies and their relation to clinical exposure.- 3 International survey on the timing of toxicity studies in relation to clinical trials.- 4 Considerations for implementing a toxicity testing strategy.- Section II: Personal Views.- 5 Phase I clinical trials: what is the minimum preclinical package necessary for initiating single-dose studies in man? — a toxicologist’s opinion.- 6 Phase I clinical trials: what is the minimum preclinical package necessary for initiating single-dose studies in man? — a clinical pharmacologist’s opinion.- 7 The duration of toxicity studies required to support repeated dosing in clinical investigation —a toxicologist’s opinion.- 8 The duration of toxicity studies required to support repeated dosing in clinical investigation — a clinician’s opinion.- 9 Reproductive and developmental toxicity studies required to support the inclusion of women and children in clinical trials — a toxicologist’s opinion.- Section III: Proposals and the Way Forward.- 10 The minimum non-clinical package for initiating Phase I clinical trials.- 11 The duration of toxicity studies to support repeated dosing in clinical investigation.- 12 The timing of reproductive toxicity studies in relation to clinical trials.- The way forward.- 14 Input to ICH.- Meeting participants.